[{"NetIncomeLoss_1_Q2_USD":-39068000.0,"OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_1_Q2_USD":0.0,"GeneralAndAdministrativeExpense_2_Q2_USD":27356000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":13539000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":932667125.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":934228095.0,"AccruedLiabilitiesCurrent_0_Q2_USD":26606000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-10385000.0,"RestrictedCashAndCashEquivalentsNoncurrent_0_Q2_USD":4632000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":69440000.0,"Depreciation_2_Q2_USD":2879000.0,"OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_2_Q2_USD":0.0,"OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_2_Q2_USD":0.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_Q2_shares":15721104.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1_Q2_shares":918048.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2_Q2_USD":-7178000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_1_Q2_USD":-4177000.0,"AssetsCurrent_0_Q2_USD":337344000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":43000.0,"CommonStockSharesIssued_0_Q2_shares":936237126.0,"Assets_0_Q2_USD":389793000.0,"ShareBasedCompensation_2_Q2_USD":10783000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":17772000.0,"OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_1_Q2_USD":0.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":2519000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":105000.0,"Liabilities_0_Q2_USD":111854000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":28868000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":-937000.0,"PrepaidExpenseCurrent_0_Q2_USD":9161000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":53000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":54000.0,"AccountsReceivableNetCurrent_0_Q2_USD":2158000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":374000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":76000.0,"CommonStockValue_0_Q2_USD":1336000.0,"ForeignCurrencyTransactionGainLossUnrealized_2_Q2_USD":267000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":-118000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":3097000.0,"CostsAndExpenses_1_Q2_USD":42407000.0,"IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_2_Q2_USD":663000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":154465000.0,"OtherAssetsCurrent_0_Q2_USD":1309000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-77168000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-39229000.0,"InterestIncomeDebtSecuritiesAvailableForSaleOperating_2_Q2_USD":691000.0,"InterestIncomeDebtSecuritiesAvailableForSaleOperating_1_Q2_USD":266000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":50453000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":19723000.0,"CostsAndExpenses_2_Q2_USD":80730000.0,"CommonStockParOrStatedValuePerShare_0_Q2_GBP":0.001,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_Q2_USD":0.75,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1_Q2_USD":0.65,"OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1_Q2_USD":-161000.0,"OtherOperatingActivitiesCashFlowStatement_2_Q2_USD":1401000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-76457000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-38992000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":5449000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":6959000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":3911000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-77999000.0,"LiabilitiesCurrent_0_Q2_USD":41416000.0,"AccountsPayableCurrent_0_Q2_USD":6977000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":34360000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":55085000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":578000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":3850000.0,"IntangibleAssetsNetExcludingGoodwill_0_Q2_USD":1382000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_0_Q2_security":0.0,"AdditionalPaidInCapital_0_Q2_USD":949575000.0,"PaymentsToAcquireIntangibleAssets_2_Q2_USD":143000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_2_Q2_USD":0.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_1_Q2_USD":0.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":28663000.0,"NetIncomeLoss_2_Q2_USD":-76831000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":49816000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":81958000.0,"CommonStockSharesOutstanding_0_Q2_shares":936237126.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-6399000.0,"CommonStockSharesAuthorized_0_Q2_shares":1240853520.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":3529000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":3095000.0,"OperatingIncomeLoss_2_Q2_USD":-77201000.0,"OperatingIncomeLoss_1_Q2_USD":-39312000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":234917000.0,"IncomeTaxesReceivable_0_Q2_USD":37755000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":4911000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":389793000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":8474000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":10783000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":5449000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":2922000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-0.08,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.04,"ProfitLoss_2_Q2_USD":-76831000.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":667000.0,"OtherLiabilitiesCurrent_0_Q2_USD":211000.0,"StockholdersEquity_0_Q2_USD":277939000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q2_USD":50048000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":2924000.0,"AllowanceForDoubtfulAccountsReceivableCurrent_0_Q2_USD":0.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-662587000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":53374000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":1946000.0,"Ticker":"ADAP","CIK":"1621227","name":"ADAPTIMMUNE THERAPEUTICS PLC","OfficialName":"Adaptimmune Therapeutics plc American Depositary Shares","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"301181409.0","Country":"United Kingdom","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20210809"}]